MEDI-522
MEDI-522 is a pharmaceutical drug with 7 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
7 of 7 finished
0.0%
0 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma
Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis
Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors
Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
Clinical Trials (7)
Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma
Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis
Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors
Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7